These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 28423632)

  • 1. The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
    Li X; Zhang R; Liu Z; Li S; Xu H
    Oncotarget; 2017 Mar; 8(12):20252-20265. PubMed ID: 28423632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
    Lin L; Zhang Z; Zhang W; Wang L; Wang J
    Int J Clin Exp Pathol; 2015; 8(10):13314-22. PubMed ID: 26722535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of genetic polymorphisms in pTEN/AKT/mTOR signaling pathway genes with cancer risk: A meta-analysis in Asian population.
    Zhang Z; Chen Q; Zhang J; Wang Y; Hu X; Yin S; He M; Guan S; Qin W; Xiao Q; Zhao H; Yao W; Wu H; Wei M
    Sci Rep; 2017 Dec; 7(1):17844. PubMed ID: 29259266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A GG allele of 3'-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer.
    Wang X; Lin Y; Lan F; Yu Y; Ouyang X; Wang X; Huang Q; Wang L; Tan J; Zheng F
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1399-411. PubMed ID: 24737346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
    Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer.
    Li Q; Yang J; Yu Q; Wu H; Liu B; Xiong H; Hu G; Zhao J; Yuan X; Liao Z
    Clin Cancer Res; 2013 Nov; 19(22):6252-60. PubMed ID: 24077347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between
    Wang Z; Fu H; Li W
    Oncol Lett; 2018 Sep; 16(3):3699-3705. PubMed ID: 30127980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
    Kim JG; Chae YS; Sohn SK; Kang BW; Moon JH; Lee SJ; Jeon SW; Park JS; Park JY; Choi GS
    Oncology; 2010; 79(3-4):278-82. PubMed ID: 21412012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy.
    Yang Y; Xu W; Liu D; Ding X; Su B; Sun Y; Gao W
    Tumour Biol; 2016 Jun; 37(6):7785-96. PubMed ID: 26695147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
    Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
    J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
    Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
    Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
    Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
    Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
    Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
    Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
    Pfisterer K; Fusi A; Klinghammer K; Knödler M; Nonnenmacher A; Keilholz U
    Head Neck; 2015 Apr; 37(4):471-8. PubMed ID: 24421178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Functional Polymorphism (rs2494752) in the AKT1 Promoter Region and Gastric Adenocarcinoma Risk in an Eastern Chinese Population.
    Wang MY; He J; Zhu ML; Teng XY; Li QX; Sun MH; Wang XF; Yang YJ; Wang JC; Jin L; Wang YN; Wei QY
    Sci Rep; 2016 Jan; 6():20008. PubMed ID: 26818920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
    Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
    PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.